𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A bispecific antibody induces efficient killing of tumor cells

✍ Scribed by R. Zeidler; G. Reisbach; S. Lang; B. Wollenberg; B. Schmitt; S. Erndl; S. Chaubal; H. Lindhofer

Book ID
117665667
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
145 KB
Volume
33
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A recombinant bispecific single-chain an
A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing
✍ Ludger Grosse-Hovest; Ingo Hartlapp; Wolfgang Marwan; Gottfried Brem; Hans-Georg 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

## Abstract Endowing tumor cells with costimulatory signals for T cell activation has emerged as a promising strategy for tumor immunotherapy. Costimulatory molecules were either transfected into tumor cells to generate vaccines or were fused, __e.g.__ to antibodies against tumor‐associated antigen

Serial killing of tumor cells by cytotox
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
✍ Patrick Hoffmann; Robert Hofmeister; Klaus Brischwein; Christian Brandl; Sandrin 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 359 KB

## Abstract Certain bispecific antibodies exhibit an extraordinary potency and efficacy for target cell lysis by eliciting a polyclonal T‐cell response. One example is a CD19‐/CD3‐bispecific single‐chain antibody construct (bscCD19xCD3), which at femtomolar concentrations can redirect cytotoxic T c

Trifunctional bispecific antibody–induce
Trifunctional bispecific antibody–induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract
✍ Silke S. Gronau; Michael Schmitt; Bernard Thess; Peter Reinhardt; Markus Wiesnet 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 598 KB

## Abstract ## Background. The trifunctional bispecific antibody Removab (tbAB) bridges and activates CD3 positive T cells to EpCAM on carcinoma cells and simultaneously binds to an accessory immune‐cell inducing tumor cell lysis. tbAB‐induced tumor cytotoxicity was assessed in an autologous human